Conference abstractPublished 12 Nov 2013
Benefit-risk balance and signal detection in the eyes of the stakeholder
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The need to achieve maximum benefit and assume the least harm had been the mainstay for human survival. The integration of all variables including new information in any decision-making is the reason for human successful evolution. Translating this in drug business language: the perception of benefit-risk (B/R) balance, which is continuously impacted by new signals (SD), is the essence of deciding on adopting any therapeutic modality. In the drug development process, a positive benefit-risk (B/R) balance is the most desired outcome on the minds of all stakeholders (pharmaceutical industry, health care providers and regulatory agencies and most importantly patients). The main element that can influence such balance is the outcome of the ongoing processes of signal detection (SD). However, the main challenges are in the differences in �perception� of such B/R balance in the eyes of each of the stakeholders in addition to the lack of consistent/transparent methodology in achieving regulatory decisions regarding B/R. The examples for such differences are worth contemplating and the need to have a consistent transparent yard stick by regulatory agencies accelerated in the last 7 years and resulted in a public law in 2012. The good news is that a real life example was delivered ahead of schedule. This speech will attempt to discuss many of the relevant points to the evaluation of these basic, yet complicated, concepts of S/D and B/R balance
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Developing Drugs
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ashraf Youssef”
